000307660 001__ 307660
000307660 005__ 20260117120453.0
000307660 0247_ $$2doi$$a10.1200/PO-25-00501
000307660 0247_ $$2pmid$$apmid:41538757
000307660 037__ $$aDKFZ-2026-00117
000307660 041__ $$aEnglish
000307660 082__ $$a610
000307660 1001_ $$00000-0002-0644-0985$$aGobits, Roán$$b0
000307660 245__ $$aFunctional Precision Medicine Using MicroOrganoSpheres for Treatment Response Prediction in Advanced Colorectal Cancer.
000307660 260__ $$aAlexandria, VA$$bAmerican Society of Clinical Oncology$$c2026
000307660 3367_ $$2DRIVER$$aarticle
000307660 3367_ $$2DataCite$$aOutput Types/Journal article
000307660 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1768575602_1240524
000307660 3367_ $$2BibTeX$$aARTICLE
000307660 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307660 3367_ $$00$$2EndNote$$aJournal Article
000307660 500__ $$aDKFZ-ZMBH Alliance / #NCTZFB26# / #DKTKZFB26# / #EA:A013#LA:A013#
000307660 520__ $$aNeoadjuvant chemotherapy is a key component of curative treatment in advanced colorectal cancer (CRC). However, 30%-40% of patients show progression on treatment, underscoring the need for predictive tools to guide up-front treatment selection. Scalable and reproducible methods for patient stratification remain limited. MicroOrganoSpheres (MOS) are droplet-encapsulated 3D tumor models that allow for high-throughput functional drug testing. Here, we evaluate the potential of tumor-derived MOS to predict response to chemotherapy in patients with CRC.MOS droplets were generated from 37 primary and/or metastatic tumor samples collected from 21 patients. MOS response to chemotherapy was quantified using AI-based imaging analysis and compared with clinical response (RECIST/disease-free survival [DFS]) and lesion-specific outcomes (pathologic response/percent tumor volume change).MOS chemoprediction assay showed high reproducibility (coefficients of variation ≤ 2.5%). MOS drug sensitivity recapitulated patient response with 83% accuracy in the full sample cohort and 100% accuracy when derived from primary tumors. Patients with sensitive MOS showed longer DFS. Individual MOS analysis revealed preservation of intratumor heterogeneity in vitro and enabled identification of drug-resistant clones.MOS technology offers a scalable and robust functional precision medicine platform with potential to guide clinical decision making in CRC. The platform accurately predicts patient response to chemotherapy and provides insights into intrapatient and intratumor heterogeneity.
000307660 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000307660 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307660 650_2 $$2MeSH$$aHumans
000307660 650_2 $$2MeSH$$aColorectal Neoplasms: drug therapy
000307660 650_2 $$2MeSH$$aColorectal Neoplasms: pathology
000307660 650_2 $$2MeSH$$aPrecision Medicine: methods
000307660 650_2 $$2MeSH$$aMale
000307660 650_2 $$2MeSH$$aFemale
000307660 650_2 $$2MeSH$$aMiddle Aged
000307660 650_2 $$2MeSH$$aAged
000307660 650_2 $$2MeSH$$aNeoadjuvant Therapy
000307660 650_2 $$2MeSH$$aTreatment Outcome
000307660 7001_ $$0P:(DE-He78)036af490355ac670feddd2b30853d029$$aSchleußner, Nikolai$$b1$$eFirst author
000307660 7001_ $$aOliver, Gavin R$$b2
000307660 7001_ $$aRutenberg Schoenberg, Michael$$b3
000307660 7001_ $$00000-0002-1803-1863$$ade Jesus Domingues, António Miguel$$b4
000307660 7001_ $$aRamkumar, Pavan$$b5
000307660 7001_ $$aSuen, Sylvia W F$$b6
000307660 7001_ $$aKoomen, Mandy P M$$b7
000307660 7001_ $$aPaolucci, Francesca$$b8
000307660 7001_ $$aMartens, Kilian$$b9
000307660 7001_ $$0P:(DE-He78)22b7d8897b7e51d6eae191944f49ad73$$aGuiseris Martinez, Aitana$$b10
000307660 7001_ $$0P:(DE-He78)aaa8eb8347aa4d45f1ac2d9968eaa8e4$$aVolk, Julia$$b11
000307660 7001_ $$0P:(DE-He78)bf2b0353d4f932e42835aafde9ba0842$$aArtmann, Carolin$$b12
000307660 7001_ $$0P:(DE-He78)d6ae2347e33f9c32d59b178a262f75bf$$aMastel, Manuel$$b13
000307660 7001_ $$0P:(DE-He78)bfd25fb9bbf13ba9c868ffc5fb634607$$aOuyang, Kyanna$$b14
000307660 7001_ $$aKloor, Matthias$$b15
000307660 7001_ $$00009-0006-2032-7651$$aBankaitis, Eric Daniel$$b16
000307660 7001_ $$aStoub, Hayden Eric$$b17
000307660 7001_ $$0P:(DE-He78)04965ffa43dd78e7f52259c5fceffefa$$aPuschhof, Jens$$b18
000307660 7001_ $$00009-0000-7139-2185$$aBrown, Kevin$$b19
000307660 7001_ $$00009-0009-0442-877X$$aPretzer, Sebastian$$b20
000307660 7001_ $$aNelson, Daniel A$$b21
000307660 7001_ $$00009-0001-1459-348X$$aStruminger, Eric$$b22
000307660 7001_ $$00009-0003-5855-9544$$aZessin, Amelia$$b23
000307660 7001_ $$aBrown, Amanda$$b24
000307660 7001_ $$aEvans, Corey$$b25
000307660 7001_ $$00009-0001-1551-0607$$aYetsko, Daniel$$b26
000307660 7001_ $$aHarrington, Mackenzie$$b27
000307660 7001_ $$00000-0002-3964-3527$$aSalg, Gabriel$$b28
000307660 7001_ $$aSchneider, Martin$$b29
000307660 7001_ $$00000-0002-7166-3675$$aSchmidt, Thomas$$b30
000307660 7001_ $$00009-0007-4096-9261$$aHelman, Elena$$b31
000307660 7001_ $$aPlenker, Dennis$$b32
000307660 7001_ $$00000-0002-5686-8357$$aBarnett, Carlton$$b33
000307660 7001_ $$aJones, Ryan T$$b34
000307660 7001_ $$0P:(DE-He78)21ee1e660035cae35605a39903143096$$aKöhler, Bruno Christian$$b35$$udkfz
000307660 7001_ $$00000-0002-4512-3106$$aDriehuis, Else$$b36
000307660 7001_ $$0P:(DE-He78)5da14633266cbfff7746cf529c110673$$aJackstadt, Rene-Filip$$b37$$eLast author
000307660 773__ $$0PERI:(DE-600)2964799-X$$a10.1200/PO-25-00501$$gVol. 10, no. 10, p. e2500501$$n10$$pe2500501$$tJCO precision oncology$$v10$$x2473-4284$$y2026
000307660 909CO $$ooai:inrepo02.dkfz.de:307660$$pVDB
000307660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)036af490355ac670feddd2b30853d029$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000307660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)22b7d8897b7e51d6eae191944f49ad73$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000307660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)aaa8eb8347aa4d45f1ac2d9968eaa8e4$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000307660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bf2b0353d4f932e42835aafde9ba0842$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000307660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d6ae2347e33f9c32d59b178a262f75bf$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000307660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bfd25fb9bbf13ba9c868ffc5fb634607$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000307660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)04965ffa43dd78e7f52259c5fceffefa$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000307660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)21ee1e660035cae35605a39903143096$$aDeutsches Krebsforschungszentrum$$b35$$kDKFZ
000307660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5da14633266cbfff7746cf529c110673$$aDeutsches Krebsforschungszentrum$$b37$$kDKFZ
000307660 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000307660 9141_ $$y2026
000307660 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJCO PRECIS ONCOL : 2022$$d2025-01-02
000307660 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000307660 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000307660 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-02
000307660 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-02
000307660 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000307660 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000307660 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000307660 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000307660 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000307660 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-02
000307660 9202_ $$0I:(DE-He78)A013-20160331$$kA013$$lNWG Tumorprogression und Metastasierung$$x0
000307660 9201_ $$0I:(DE-He78)A013-20160331$$kA013$$lNWG Tumorprogression und Metastasierung$$x0
000307660 9201_ $$0I:(DE-He78)D300-20160331$$kD300$$lNWG Epithel-Mikrobiom-Interaktionen$$x1
000307660 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000307660 9201_ $$0I:(DE-He78)HD02-20160331$$kHD02$$lKoordinierungsstelle NCT Heidelberg$$x3
000307660 9200_ $$0I:(DE-He78)A013-20160331$$kA013$$lNWG Tumorprogression und Metastasierung$$x0
000307660 980__ $$ajournal
000307660 980__ $$aVDB
000307660 980__ $$aI:(DE-He78)A013-20160331
000307660 980__ $$aI:(DE-He78)D300-20160331
000307660 980__ $$aI:(DE-He78)HD01-20160331
000307660 980__ $$aI:(DE-He78)HD02-20160331
000307660 980__ $$aUNRESTRICTED